98%
921
2 minutes
20
An ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was established to determine -(1,3-dimethylbutyl)--phenyl--phenylenediamine-quinone (6PPD-Q) in human urine and dust in order to understand the internal and external exposure levels in humans. The sample preparation conditions were systematically investigated and the chromatographic conditions and MS parameters were optimized. Briefly, internal standard C-6PPD-Q (0.1 ng) was added to a urine sample. Glutathione and NaCl were added after equilibration for 30 min. The mixture was then twice ultrasonically extracted with ethyl acetate. Internal standard C-6PPD-Q (1.0 ng) was also added to a dust sample and the mixture was twice ultrasonically extracted with -hexane. The combined organic phases were concentrated to near-dryness and then redissolved for instrumental determination, which was performed on a Phenomenex Kinetex F5 column (100 mm×3 mm, 2.6 μm), with the target analyte gradient eluted using 10 mmol/L ammonium acetate aqueous solution containing 0.01% formic acid and acetonitrile. Positive electrospray ionization (ESI) and multiple reaction monitoring (MRM) modes were used for identification purposes, and an isotope-labeled internal standard was added for quantification. Good linearities were achieved under the optimized conditions within the 0.01-4.00 and 0.01-20.0 μg/L ranges for urine and dust, respectively, with correlation coefficients of 0.999 9 and 0.999 3, respectively. Limits of detection (LODs) were 0.6 ng/L (urine) and 0.018 ng/g (dust). Spiked recoveries of 6PPD-Q were 90.3%-94.1% at low, medium, and high spiked levels, with intra-day and inter-day precisions of 0.9%-5.9% and 1.1%-6.3%, respectively. Matrix-effect investigations revealed that 6PPD-Q exhibited weak matrix effects in urine and dust after correction with the isotopic internal standard. The developed method was used to analyze 120 human urine samples, which led to a 6PPD-Q detection frequency of 74.2%, with mass concentrations ranging from
Download full-text PDF
Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412019 PMC http://dx.doi.org/10.3724/SP.J.1123.2025.02010 DOI Listing Publication Analysis
Top Keywords
Acta Vet Hung
September 2025
4Department of Internal Medicine, University of Veterinary Medicine Budapest, István Street 2, 1078 Budapest, Hungary.
The low dose dexamethasone stimulation test (LDDST) is routinely used in canine medicine but in the few cases in guinea pigs diagnosed with hypercortisolism, the adrenocorticotropic hormone (ACTH) stimulation test was used. The objective of the authors was to conduct a pilot study and find out if the standard test used in dogs can be used in this species.A 4-year-old intact female hairless guinea pig showed bilaterally enlarged adrenal glands and high cortisol levels.
View Article and Find Full Text PDFJMIR Res Protoc
September 2025
Department of Health Services Research & Administration, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States.
Background: With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC.
View Article and Find Full Text PDFJMIR Res Protoc
September 2025
Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Background: In pediatric intensive care units, pain, sedation, delirium, and iatrogenic withdrawal syndrome (IWS) must be managed as interrelated conditions. Although clinical practice guidelines (CPGs) exist, new evidence needs to be incorporated, gaps in recommendations addressed, and recommendations adapted to the European context.
Objective: This protocol describes the development of the first patient- and family-informed European guideline for managing pain, sedation, delirium, and IWS by the European Society of Paediatric and Neonatal Intensive Care.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFHead Neck Pathol
September 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Myoepithelial carcinoma (MECA) is a malignant neoplasm composed exclusively of myoepithelial cells and accounts for less than 1% of all salivary gland tumors. Its diagnosis is often challenging due to histologic overlaps with benign lesions and its variable morphologic presentation. Although molecular profiling has emerged as a valuable tool in salivary gland tumor classification, the genetic landscape of MECA remains incompletely defined.
View Article and Find Full Text PDF